Novel HER3 Agents for EGFR Mutated NSCLC

CME

New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: December 17, 2024

Expiration: June 16, 2025

Karen Reckamp
Karen Reckamp, MD, MS
Helena Yu
Helena Yu, MD

Activity

Progress
1 2
Course Completed

Introduction 

In this module, Karen Reckamp, MD, MS, and Helena Yu, MD, discuss the current treatment landscape of advanced, nonsquamous EGFR-mutated non-small-cell lung cancer (NSCLC), unmet needs after progression on first-line EGFR tyrosine kinase inhibitor (TKI) therapy, the significance of clinical trial referral for improved patient care, and new HER3-targeting agents.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with NSCLC do you provide care for in a typical week? 

Based on the HERTHENA-Lung02 trial, which of the following patients with advanced, nonsquamous, NSCLC would be a likely candidate for treatment with patritumab deruxtecan (HER3-DXd)?